RESEARCH TRIANGLE PARK, N.C., May 11, 2012 /PRNewswire/ -- Stiefel, a GSK (GSK) company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%. It is the only retinoid in a topical foam formulation for the treatment of acne vulgaris in patients 12 years of age and older.
"Stiefel is dedicated to meeting the needs of patients and dermatologists and we believe Fabior Foam will be an important treatment option for people with moderate-to-severe acne," said Jean-Christophe May, Vice President, North America Dermatology.
The approval of tazarotene foam was based on two multi-center, randomized, double-blind, vehicle-controlled pivotal Phase 3 studies conducted in the US and Canada. More information about the clinical trial results can be found in the Full US Prescribing Information at http://www.stiefel.com/content/dam/stiefel/globals/documents/pdf/US_Fabior.pdf.
Tazarotene foam is contraindicated in pregnancy and may cause fetal harm when administered in pregnant women. The most common adverse reactions reported at an incidence > 6% were application site irritation, application site dryness, application site erythema, and application site exfoliation.
About Acne Vulgaris
Acne is the most common skin problem in the US, affecting about 40 – 50 million Americans at any one time. Acne can affect anyone at any age but it is most common in adolescents and young adults. Hormones and other substances can act on the skin's oil (sebaceous) glands and hair follicles, leading to clogged pores and outbreaks commonly known as pimples. While the exact cause of acne is unknown, researchers believe it results from several factors, including hormonal changes, heredity and genetics, certain medications, and greasy cosmetics.
Important Safety Information
Fabior Foam is contraindicated in pregnancy and may cause fetal harm when administered in pregnant women. Females of childbearing potential should have a negative pregnancy test within two weeks prior to initiating treatment and use an effective method of contraception during treatment.
It should be used with caution in patients with a history of local tolerability reactions or local hypersensitivity. Concomitant topical acne therapy should be used with caution because a cumulative irritant effect may occur. Because of increased photosensitivity and risk of sunburn, patients should avoid exposure to sunlight, sunlamps, and weather extremes, and should wear sunscreen daily. The propellant in Fabior Foam is flammable so patients should be instructed to avoid fire, flame, and smoking during and immediately following application. The most common adverse reactions reported at an incidence ≥ 6% are application site irritation, application site dryness, application site erythema, and application site exfoliation.
For more information about Fabior Foam please see the Full US Prescribing Information at http://www.stiefel.com/content/dam/stiefel/globals/documents/pdf/US_Fabior.pdf
GlaxoSmithKline plc – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
Stiefel, a GSK company – is committed to advancing Dermatology and skin science around the world in order to help people better achieve healthier skin. Stiefel's dedication to innovation, along with its focus on pharmaceutical, over-the-counter and aesthetic Dermatology products, has established Stiefel as a world leader in the skin health industry. To learn more about Stiefel, visit www.stiefel.com.Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2011.
 American Academy of Dermatology. Acne: Who gets and causes. Available at http://www.aad.org/skin-conditions/dermatology-a-to-z/acne/who-gets-causes/acne-who-gets-and-causes. Accessed 26 April, 2012.
 US Department of Health and Human Services, National Institutes of Health, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Questions and Answers about Acne. October 2010. Available at http://www.niams.nih.gov/Health_Info/Acne/default.asp. Accessed 26 April, 2012.
|07:05 AM||Thank You Metro Detroit! 30,000 took part in the 22nd Annual Komen Detroit Race for the Cure®, May 18. Fundraising Continues through July 1.|
|07:04 AM||Greenfield Farms Announces Scheduled Closing Of Carmela's Pizzeria Acquisition For June 5, 2013|
|07:01 AM||Mobile Broadband Provider iTalk set to Launch Dealer Program with Residuals|
|07:00 AM||The Midnight Sun Never Sets in Norway|
|07:00 AM||The Midnight Sun Never Sets in Norway|
|07:00 AM||Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference|
|07:00 AM||FRC Ad Urges Boy Scout Delegates to Reject Resolution, Preserve Scouting's Timeless Values|
|07:00 AM||CB&I to Present at 2013 Credit Suisse Engineering & Construction Conference|
|07:00 AM||Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease|
|07:00 AM||Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment|
|07:00 AM||Goodyear Kicks Off 4th Annual 'Gives Back' Campaign|
|07:00 AM||Former Joint Commission Executive To Lead TeleTracking Consulting Services|
|07:00 AM||Picarro Demonstrates Its Cutting-edge Leak Detection Technology At EPA's Natural Gas Star Workshop|
|07:00 AM||Securities And Commercial Litigation Expert Paul Hinton Joins The Brattle Group|
|07:00 AM||May 2013 New Car Sales Expected to Be Up Almost Nine Percent According to TrueCar; May 2013 SAAR at 15.2M, Highest May SAAR Since 2007|
|07:00 AM||Ritchie Bros. to sell more than 70 trucks for Walmart at unreserved public auction in Chicago, IL on May 30|
|07:00 AM||Biorem Reports 3rd Consecutive Quarter with Positive EBITDA|
|07:00 AM||Michaels Stores, Inc. Reports First Quarter Results|
|07:00 AM||Microsemi Unveils New Family of High-Security, Self-encrypting Solid State Drives|
|07:00 AM||Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference|
|07:00 AM||Cato Reports 1Q EPS Down 3%|
|07:00 AM||U.S. Army Launches "Starting Strong"|
|07:00 AM||Win £500 with New Look and the High Street Fashion Awards|
|07:00 AM||Bengal Energy to Form Strategic Joint Venture with Beach Energy Ltd. for Cooper Basin Exploration and Development Program|
|07:00 AM||Are you ready? Financial services regulation reforms may catch some organizations off guard|
|06:50 AM||Jean Chatzky and RetailMeNot to Continue Educational Partnership to Promote Financial Literacy Education|
|06:45 AM||Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition|
|06:36 AM||RRsat Extends Distribution of Word Network to Australia, New Zealand and the Arab World|
|06:32 AM||TD Bank Group Declares Dividends|
|06:31 AM||Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share|
|More Press Releases From PR Newswire|